Evotec Extends Integrated Drug Discovery Alliance With Genentech
News May 24, 2016

Evotec AG has announced that Genentech has extended its integrated drug discovery alliance with Evotec for a further three years to discover novel small molecule therapeutics.
The collaboration initiated in May 2010 was renewed in 2013 and this second extension further validates the value of Evotec's state-of-the-art technology platform and broad expertise in drug discovery. Activities performed within the collaboration include pharmacology, screening, chemistry, proteomics and structural biology.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are delighted that once again we have extended this fruitful collaboration beyond its 7th year and this latest extension is validation of the value Evotec brings to this partnership. With an increasing portfolio of activities, the scientific teams from both companies are working closely together to effectively and efficiently advance Genentech's discovery projects."
No financial details were disclosed.
FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
RELATED ARTICLES
Neuropeptide Y Y1 Receptor Structure Solved, Offers New Opportunities for Anti-obesity Drug Discovery
NewsScientists solve the crystal structure of Neuropeptide Y Y1 Receptor, offering new opportunities for anti-obesity drug discovery.
READ MORECrystal Structure of Neuropeptide 1 Receptor Solved, Providing Therapeutic Angle For Obesity Treatment
NewsAn international team has uncovered the potential to beat obesity at the cellular level, characterizing for the first time a complex, little-understood receptor type that, when activated, shuts off hunger.
READ MOREPost-Stroke Intranasal (+)-Naloxone Improves Stroke Outcome
NewsThe life-saving drug used to treat opioid overdose, naloxone, reduces brain inflammation in the aftermath of stroke in male rats.
READ MOREComments | 0 ADD COMMENT
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREEWorld Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
29th International Conference on Public Mental Health and Neuroscience
Jul 16 - Jul 18, 2018
Login
You must be logged in to post a comment.